Side effects when changing from Mounjaro to Wegovy: what to expect

Does switching medicines mean the side effects start again from scratch?

This is the question our prescribers hear most often from people mid-switch. The short answer is: possibly, yes, at least partially. Mounjaro (tirzepatide) activates both the GIP and GLP-1 receptors; Wegovy (semaglutide) works only on GLP-1. Your body has been adapting to that dual signal, and introducing a different hormonal input (even a related one) can prompt a fresh wave of gastrointestinal adjustment.

The most commonly reported side effects for both medicines are GI-led: nausea, loose stools, constipation, reflux and burping. These tend to arrive after a dose increase or a medicine change, and they typically settle within days to a couple of weeks as the body recalibrates. That said, everyone's response is individual. Some people find the transition barely noticeable; others experience a more pronounced reset period, particularly if they are beginning Wegovy at the standard starting dose rather than transferring at a comparable level.

It is worth noting that Wegovy is titrated from 0.25mg upward, and the prescriber decides the most appropriate starting point for transfer patients. The practical experience of moving from Mounjaro to Wegovy depends heavily on where in that titration you begin. Rushing straight to a higher dose to preserve results tends to increase tolerability problems, a clinical discussion before switching matters.

How do the side-effect profiles of the two medicines actually differ?

Both share a broadly similar list, but there are meaningful nuances worth knowing. The table below draws on trial data and licensed prescribing information from the eMC and NICE appraisals.

The relative frequency figures across those rows are broadly similar, neither medicine has a substantially cleaner GI record than the other in head-to-head terms. What tends to differ is the subjective experience: some people find the GIP component of tirzepatide moderates nausea compared with GLP-1 alone; others report the opposite. The detailed tolerability comparison between the two covers this variability more fully. Neither outcome can be predicted in advance, which is exactly why the switch should happen under clinical oversight rather than independently.

Are there specific risks to watch for in the gap between stopping one and starting the other?

Mounjaro's active period in the body extends beyond a week, the pharmacokinetic half-life of tirzepatide is approximately five days, meaning meaningful levels remain for several weeks after the last dose. If you stop Mounjaro and begin Wegovy immediately, you may have overlapping drug exposure during the transition, which can intensify GI effects in the short term. Conversely, a long gap risks losing the metabolic ground you've gained.

Your prescriber weighs those factors. There is no universally correct overlap window; the right interval depends on the dose you were on, your tolerability history and the dose level Wegovy is introduced at. Alongside this, the process of switching medicines has practical considerations around pen storage too. Wegovy pens, like Mounjaro, should be kept in the fridge at 2–8°C (so the same spot on the fridge door that became routine with one medicine works for the other) though the exact room-temperature window before use differs between them, and the Patient Information Leaflet for each is the definitive reference on that detail.

For the serious but rare side effects (pancreatitis symptoms (severe, persistent stomach pain spreading to the back, with or without vomiting), signs of gallbladder problems, or a significant allergic reaction) the guidance is the same regardless of which medicine is involved: seek urgent medical help and report to the MHRA Yellow Card scheme. Changing medicine does not reduce that vigilance requirement; if anything, the transition window is a time to pay closer attention.

Which medicine's side-effect profile is better suited to you?

That is genuinely not a question this page can answer. The SURMOUNT-5 trial (published in the New England Journal of Medicine, 2025) showed tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, but trial averages describe populations, not individuals. Tolerability is personal, and for some people, the side-effect experience on Mounjaro is worse than on Wegovy, or vice versa. The right switch is the one a prescriber makes with a full picture of your history, current dose and health profile.

You can explore the broader clinical differences between Wegovy and Mounjaro on their own terms. For pricing context, the reason Wegovy typically costs less than Mounjaro is covered separately. Both medicines are available privately through a free consultation with our prescribers; the clinical team (including our clinical lead) reviews each case individually. Which suits you is a clinical decision our prescribers make with you.